There are 2789 resources available
345MO - Treatment associated changes in the inflammatory microenvironment composition of brain metastases
Presenter: Ariane Steindl
Session: Mini oral session - CNS tumours
Resources:
Abstract
Slides
Webcast
346MO - Safety of idroxioleic acid in combination with standard of care (temozolomide and/or radiation therapy) in newly diagnosed glioblastoma patients: A phase Ib trial
Presenter: Carme Balaña
Session: Mini oral session - CNS tumours
Resources:
Abstract
Slides
Webcast
1743MO - MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation
Presenter: Sophie Leboulleux
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1099MO - Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
Presenter: Jorge Hernando
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
347MO - 5-Aminolevulinic acid sonodynamic therapy in recurrent glioblastoma: A first-in-human phase 0/1 clinical trial
Presenter: Nader Sanai
Session: Mini oral session - CNS tumours
Resources:
Abstract
Slides
Webcast
LBA12 - Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial
Presenter: Giampaolo Bianchini
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
120MO - Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials
Presenter: Aranzazu Fernandez-Martinez
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA14 - Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study
Presenter: Sara Hurvitz
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Polling 2 (led by chair)
Presenter: Edward Garon
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Edward Garon
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast